In a phase 1/2 trial, olutasidenib monotherapy-induced durable responses with an overall response rate around 35–40% in patients with relapsed/refractory IDH1-mutated AML, including some complete remissions, with a manageable safety profile [52]. Here, IDH1 is linked to acute myeloid leukemia.